Targeting mTOR in renal cell carcinoma (Q37463917)

20 August 2017

1 reference

title

Targeting mTOR in renal cell carcinoma (English)

1 reference

20 August 2017

Gary R Hudes

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

115

1 reference

20 August 2017

issue

10 Suppl

1 reference

20 August 2017

page(s)

2313-2320

1 reference

Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

Activation of AKT kinases in cancer: implications for therapeutic targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

The biology and clinical relevance of the PTEN tumor suppressor pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

TOR, a central controller of cell growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Complexity of the TOR signaling network

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Activation of the mTOR signaling pathway in renal clear cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24239

7 January 2021

Identifiers

DOI

10.1002/CNCR.24239

1 reference

20 August 2017

1 reference